New insider activity at Relay Therapeutics ( (RLAY) ) has taken place on October 30, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In a series of notable transactions involving Relay Therapeutics stock, President of R&D Donald A. Bergstrom sold 30,897 shares, amounting to $225,239. Meanwhile, CFO Thomas Catinazzo parted with 21,664 shares, totaling $157,930. Additionally, Chief Corporate Development Officer Peter Rahmer sold 40,529 shares, bringing in $299,949.
Spark’s Take on RLAY Stock
According to Spark, TipRanks’ AI Analyst, RLAY is a Neutral.
The overall stock score for Relay Therapeutics is primarily influenced by its technical analysis, which shows strong upward momentum. However, this is offset by poor financial performance and valuation concerns due to ongoing losses and lack of profitability. The absence of earnings call data and corporate events means these factors do not impact the score.
To see Spark’s full report on RLAY stock, click here.
More about Relay Therapeutics
YTD Price Performance: 70.0%
Average Trading Volume: 1,734,330
Technical Sentiment Signal: Buy
Current Market Cap: $1.26B